Akzo Nobel NV has reported a robust third-quarter performance, revealing organic sales growth and a sixth consecutive quarter of margin expansion. This comes as the company is on track to finalize its merger with Axalta, a move that is expected to enhance its market position in the chemicals sector.

In its latest filing, the company highlighted that its organic sales grew by 2% on pricing, although total revenue remained flat. Operating income was affected by the deconsolidation of its Russian entities and the divestment of its operations in Pakistan. Despite these challenges, Akzo Nobel's adjusted EBITDA grew by €15 million, with the adjusted EBITDA margin increasing to 15.3% compared to 15.1% in the previous year.

Background

Akzo Nobel NV, a leading player in the chemicals industry, is primarily involved in the production of paints and coatings. The company operates under the SIC classification of 2800, which encompasses Chemicals & Allied Products. Akzo Nobel trades on the OTC markets under the tickers AKZOY and AKZOF. Its recent filings include several 6-K forms and media releases detailing its financial performance and strategic initiatives.

What the Filing Says

The filing dated October 21, 2026, states, "AkzoNobel delivered another strong quarter, with organic sales and adjusted EBITDA both increasing." CEO Greg Poux-Guillaume emphasized the company's ability to realize pricing in challenging markets and noted the successful divestment of its Decorative Paints business in South East Asia for $1.35 billion, which he described as a significant value unlock.

Impact

This update may impact various stakeholders, including investors and competitors in the chemicals sector. The successful divestment and merger strategies could set a precedent for similar companies looking to streamline operations and enhance profitability. Akzo Nobel's performance may also influence market perceptions of stability and growth potential within the industry.

What's Next

The filing does not say what happens next, but the company anticipates closing the merger with Axalta in early 2027, pending regulatory approvals.